Título Abreviado: E.O. 21/728
Investigador Principal: María Victoria Mateos Manteca
Código EUDRACT:
Código Identificativo: ECI2021/0093

GEM-OPTIMAL

A prospective, observational study, to evaluate the maintenance with bortezomib plus daratumumab (V-Dara) after induction with bortezomib, melphalan, prednisone plus daratumumab (VMP-Dara) in newly diagnosed multiple myeloma (MM) patients non-eligible for autologous stem cell transplantation (ASCT): Alcyone-optimized Real World Evidence (RWE) data.

Estado: ACTIVO

Pin It en Pinterest